Skip to main content

Table 1 Baseline characteristics of patients who received once-weekly teriparatide injections for 18 months

From: Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates

Sex (n) Female: 7, male: 2
Age (year) 57.4 ± 11.1
Disease (n) SLE 6, RA 2, AOSD 1
PSL dose at baseline (mg/day) 10 ± 6.6
Fracture events within 18 months before TPTD treatment (n) 8 events of 7 patients
Lumbar spine YAM (%) 73.1 ± 11.9
Total hip YAM (%) 72 ± 10.0
Lumbar spine BMD 0.74 ± 0.11
Total hip BMD 0.62 ± 0.11
Ca (mg/dl) 9.1 ± 0.5
BAP (µg/L)
Reference value; male 3.7–20.9, Premenopausal female 2.9–14.5, Postmenopausal female 3.8–22.6
10.8 ± 4.6
Serum NTx (nmol BCE/L)
Reference value; Male 9.5–17.7, Premenopausal female 7.5–16.5, Postmenopausal female 10.7–24.0
13.8 ± 4.4
FRAX: major fracture (%) 20.5 ± 16.7
FRAX: hip fracture (%) 8.8 ± 11.4
  1. Data are shown as mean ± SD
  2. SLE systemic lupus erythematosus, RA rheumatoid arthritis, AOSD adult onset still disease, PSL prednisolone, YAM young adult mean, BMD bone mineral density, Ca calcium, BAP bone alkaline phosphatase, NTx type 1 collagen cross-linked N-telopeptide